Uloric Recall Urged Over Cardiovascular Risks by Public Citizen

A prominent consumer watchdog group is calling for a Uloric recall to be issued by federal drug regulators, due to the growing scientific evidence that indicates side effects of the gout drug may increase the risk of heart attack, stroke and death. 

Public Citizen urged a panel of FDA advisers to tell the agency to ban Uloric (febuxostat) at a recent hearing over the drug’s safety issues, saying that it provides no real benefits and increases the risk of dying from cardiovascular causes.

On Monday, the FDA’s Arthritis Advisory and Drug Safety and Risks Management Advisory committees held joint hearings on Uloric safety risks, ending in a 19 to 2 vote advising the agency to make it mostly a second-line drug for those who cannot tolerate other gout medications. The panel determined that Uloric’s heart risks were too high for most patients, but that a small population could potentially make use of the drug.

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Learn More

Uloric is used to help lower uric acid in patients with gout. However, post-market clinical trials indicate patients who take Uloric face an increased risk of suffering death from cardiovascular problems, such as heart attack or stroke.

For that reason, the FDA panel recommended Uloric be used as second-line treatment for general gout patients, and only as a first-line treatment in specific cases. However, a Uloric recall was not recommended by the panel.

While the FDA is not required to follow the recommendation of the advisory committee, the agency typically does.

Public Citizen called for a complete Uloric recall, and filed a petition (PDF) to have the drug banned from the market due to its health risks back in June 2018. Dr. Michael Carome, director of Public Citizen’s Health Research Group, submitted testimony (PDF) to the FDA advisory committees last week, calling for the advisers to recommend FDA act on his group’s petition.

In his testimony, Carome noted that the FDA had concerns about Uloric before it was even approved, resulting in post-marketing study requirements which appear to confirm high heart risks due to Uloric side effects.

Carome noted that the FDA would have almost certainly denied approval to the drug if it had known about the heart problems before it hit the market.

“The results of the FDA-mandated postmarket trial provide additional high-quality evidence of a causal link between treatment with febuxostat and increased risk of all-cause death and cardiovascular death,” he noted. “Consistent with the precautionary principle of public health, we strongly urge the committee to recommend that the FDA grant our citizen petition and remove febuxostat from the market.”

On Monday, panel members agreed with Carome that if the data from the recent clinical trial was available in 2008, when the drug was first approved, Uloric wouldn’t have been approved at all.

Concerns regarding the gout drug were raised after the FDA issued a safety warning in 2017. The warning indicated the agency was investigating deaths linked to Uloric, including cardiovascular deaths and deaths related to interactions with other drugs, including bone marrow failure, severe bleeding and kidney failure.


Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Leadership Development Committee for Suboxone Dental Injury Lawyers Established in Federal MDL
Leadership Development Committee for Suboxone Dental Injury Lawyers Established in Federal MDL (Posted 2 days ago)

The U.S. District Judge presiding over all Suboxone lawsuits has created a mentorship program to use the litigation to provide some attorneys an opportunity to gain experience in handling complex federal multidistrict litigations.

Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M
Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M (Posted 4 days ago)

Gilead says it will pay $40 million to resolve HIV drug lawsuits over Truvada, Atripla, Viread, Stribild and Complera pending in the federal court system, involving claims that the the company sat on safer formulations of the drugs for years to increase profits.